Health In Tech Announces New Partnerships to Use AI-Powered Platform to Launch New Self-Funded Health Plan
The health-tech company is teaming up with Vitable and MARPAI on the project.
Stock.adobe.com
Health In Tech announced new partnerships that it says will allow it to introduce a new self-funded health plan.1 The Insurtech platform company is working with Vitable, direct primay care health plan provider, and MARPAI, a technology platform focused on health plan services. Health In Tech plans to provide those companies’ services with its eDIYBS platform to set pricing standards.
In a press release announcing the collaboration, Health In Tech’s chief growth officer Glenn Hillyer said, “This collaboration exemplifies our commitment to revolutionizing healthcare access and affordability. By integrating Vitable's hybrid DPC model–with their successful track record in effectively managing primary care and urgent care claims for self-funded and level-funded plans–with MARPAI's self-funded health plans, and the streamlined process for which Health In Tech is known for, we are working to deliver competitive value and comprehensive care to our clients."
Steven Baek, head of growth at Vitable, added, “We are excited to join forces with Health In Tech and MARPAI to bring our high-quality health plans at a significantly lower cost. Our commitment is to enhance member satisfaction and utilization while driving down healthcare costs."
MARPAI’s vice president of strategic accounts Ben Utz also said, “We are excited to announce our collaboration with both Health In Tech and Vitable, two leaders in the employee benefits space. Together, we hope to deliver smarter, seamless healthcare experiences that prioritize employee well-being, improve access to personalized care, and drive meaningful results for organizations."
This is just Health In Tech’s latest collaboration. In July of last year, the company announced a partnership with Adena Health and OSU Health Plan Solutions to bring new health plan options to employers in south-central Ohio.2
In a press release issued at the time, Hillyer said, “We are thrilled to collaborate with Adena Health and OSU Health Plan Solutions to offer these innovative level-funded health plans. This partnership underscores our commitment to providing employers with cost-effective health solutions that manage risks and deliver significant savings. Together, we are transforming the healthcare landscape in Ohio, making quality care more accessible and affordable for all."
Sources
- Health In Tech Announces Innovative Collaboration with MARPAI and Vitable DPC to Offer Competitive Quotes in Enhanced Self-Funded Solutions. Health In Tech. January 22, 2025. Accessed January 27, 2025. https://www.prnewswire.com/news-releases/health-in-tech-announces-innovative-collaboration-with-marpai-and-vitable-dpc-to-offer-competitive-quotes-in-enhanced-self-funded-solutions-302357907.html
- Health In Tech, Adena Health, and OSU Health Plan Solutions Partner to Bring Affordable Level-Funded Health Plans to Ohio Employers. Health In Tech. July 2, 2024. Accessed January 27, 2025. https://www.prnewswire.com/news-releases/health-in-tech-adena-health-and-osu-health-plan-solutions-partner-to-bring-affordable-level-funded-health-plans-to-ohio-employers-302187827.html
Asembia 2025: Therapy Advancements Highlight Growing Cost and Access Concerns
April 30th 2025Fran Gregory, VP, emerging therapies, Cardinal Health, discusses the evolving cell and gene therapy landscape, highlighting pipeline growth, cost challenges, and emerging therapeutic areas beyond oncology and hematology.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
FDA Approves AbbVie’s Rinvoq as First Oral JAK Inhibitor for Giant Cell Arteritis
April 30th 2025AbbVie secures FDA approval for Rinvoq as the first oral Janus kinase inhibitor indicated for giant cell arteritis, expanding its immunology portfolio and signaling strategic growth opportunities in underserved autoimmune markets.
